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STUDY PROTOCOL Open Access
A study protocol to assess the feasibility of
conducting an evaluation trial of the
ADVANCE integrated intervention to
address both substance use and intimate
partner abuse perpetration to men in
substance use treatment
Gail Gilchrist1*, Sabine Landau2, Polly Radcliffe1, Mary McMurran3, Gene Feder4, Caroline Easton5, Steve Parrott6,
Sara Kirkpatrick7, Juliet Henderson1, Laura Potts2, Danielle Stephens-Lewis8, Amy Johnson9, Beverly Love1,
Gemma Halliwell4, Sandi Dheensa4, Cassandra Berbary5, Jinshuo Li6, John Strang1 and Elizabeth Gilchrist9
Abstract
Background: Strong evidence exists that substance use is a contributory risk factor for intimate partner abuse (IPA)
perpetration. Men in substance use treatment are more likely to perpetrate IPA than men from the general
population. Despite this, referral pathways are lacking for this group. This trial will assess the feasibility of
conducting an evaluation trial of a tailored integrated intervention to address substance use and IPA perpetration
to men in substance use treatment.
(Continued on next page)
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Methods/design: ADVANCE is a multicentre, parallel-group individually randomised controlled feasibility trial, with
a nested formative evaluation, comparing an integrated intervention to reduce IPA + substance use treatment as
usual (TAU) to TAU only. One hundred eight men who have perpetrated IPA in the past 12 months from
community substance use treatment in London, the West Midlands, and the South West will be recruited.
ADVANCE is a manualised intervention comprising 2–4 individual sessions (2 compulsory) with a keyworker to set
goals, develop a personal safety plan and increase motivation and readiness, followed by a 12-session weekly group
intervention delivered in substance use services. Men will be randomly allocated (ratio 1:1) to receive the ADVANCE
intervention + TAU or TAU only. Men’s female (ex) partners will be invited to provide outcome data and offered
support from integrated safety services (ISS). Regular case management meetings between substance use and ISS
will manage risk. Outcome measures will be obtained at the end of the intervention (approximately 4 months post-
randomisation) for all male and female participants. The main objective of this feasibility trial is to estimate
parameters required for planning a definitive trial including rates of consent, recruitment, and follow-up by site and
group allocation. Nested formative evaluation including focus groups and in-depth interviews will explore the
intervention’s acceptability to participants, group facilitators, keyworkers and ISS workers. Secondary outcomes
include substance use, IPA, mental health, self-management, health and social care service use, criminal justice
contacts, and quality of life.
Discussion: Findings from this feasibility trial will inform the design of a multicentre randomised controlled trial
evaluating the efficacy and cost-effectiveness of the ADVANCE intervention for reducing IPA and improving the
well-being of female (ex)partners.
Background
Intimate partner abuse (IPA) includes any incident/pat-
tern of incidents of controlling, coercive or threatening
behaviour, violence, or abuse between current or former
partners [1]. Women are more likely to experience sex-
ual violence, injury, or be murdered by a partner than
men [2–5]. While no single factor explains why some
people perpetrate IPA [6, 7], there is strong and consist-
ent evidence that substances, particularly alcohol, co-
caine, and methamphetamines are contributory risk
factors for IPA perpetration [8–16]. This association is
significantly stronger from men who abuse or are
dependent on alcohol or drugs [16]. The complex inter-
play between substance use and IPA perpetration in-
cludes intoxication (change or disinhibition when under
the influence of alcohol or stimulant drugs), withdrawal
and craving (irritability and frustration or the need to ac-
quire substances), the impact of substance use on rela-
tionships, the wider dynamics of power and control, and
psychological vulnerabilities (adverse childhood experi-
ences, mental health, and emotional instability) linked to
substance use and IPA [17, 18]. At least 3 in 10 men re-
ceiving substance use treatment have been physically or
sexually violent, and 7 in 10 men have been psychologic-
ally abusive towards their partner in the previous year
[3, 8, 9, 19–21]. These rates are far higher than amongst
the general population [12, 14]. Around three-quarters
of men attending substance use treatment in England
had ever perpetrated any IPA towards their partner [9].
Despite the association between IPA perpetration and
substance use, and the higher prevalence of IPA
perpetration amongst men receiving substance use treat-
ment, there is a lack of care pathways including perpetra-
tor programmes for this client group [22]. Community
perpetrator programmes in England (UK) meet only 10%
of the existing demand [23]. Men who use substances are
rarely referred to perpetrator programmes and when they
are, treatment completion is low and attendance/uptake
poor [24–27]. In one US study, only 17% of 658 men seek-
ing alcohol treatment who had perpetrated IPA in the past
year were referred to a perpetrator programme by the al-
cohol treatment service, and only 15 (13%) enrolled in the
programme [27]. Amongst 286 males convicted for intim-
ate partner violence and court-mandated to attend a
community-perpetrator programme in Spain, a signifi-
cantly higher rate of intervention drop-out was reported
amongst men with alcohol problems (36% vs. 23%, p <
.05) [26].
Few perpetrator interventions have been trialled
amongst men who use substances [28]. A recent review
of interventions to reduce IPA perpetration by men use
substances identified only nine trials, three of which
were conducted in substance use treatment services and
two of these amongst men who had been arrested for
IPA or court-mandated to receive the intervention [28].
Initial reviews of IPA interventions conducted concur-
rently with alcohol treatment [29] or integrated inter-
ventions that address both IPA and substance use [28]
show some promise but were not superior to treatment
as usual [28]. Some interventions to address IPA in men
who use substances present a simplistic model of inebri-
ated physical violence and struggle to integrate issues of
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gender, non-physical abuse and to fully consider the im-
pact of a substance use lifestyle. Recent research has
identified that it is not one factor that explains causal
pathways into IPA, but rather a multilevel and multifac-
tor explanation is required [17, 18, 30]. A nested eco-
logical model identifies factors at 4 levels, including
structural factors such as patriarchy, sub-cultural factors,
for example, high tolerance for general alcohol use, fa-
milial factors, including modelling from family of origin
and social learning theory, and individual factors such as
high anger or high impulsivity [31]. This multifactorial
response requires a more nuanced understanding of the
roles of substance use in IPA perpetration that is wider
than intoxicated abuse. Withdrawal and craving present
as many risks as intoxication and intensify coercive con-
trol [18]. Many perpetrators report psychological prob-
lems and explain IPA as a shared response to anxiety or
depression and anger, often from emotional insecurities
shaped by negative childhood experiences, and mediated
by substances [17].
Rationale
IPA is not routinely identified or addressed in substance
use treatment, resulting in a large proportion of perpe-
trators who might benefit from treatment being missed.
Ultimately, training substance use treatment staff to de-
liver integrated interventions to address IPA in sub-
stance use treatment services would increase their reach.
We are not aware of any UK-based randomised con-
trol trials of the effectiveness of perpetrator programmes
for men who use substances. Further research is needed
to develop and test integrated interventions that address
IPA and substance use concurrently. The provision of
strategies to holistically address both may be more ef-
fective [32].
Methods
The protocol (Version 5, 13 November 2018) complies
with the guidelines of the Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) [33]
(Table 1).
Aim
This trial will assess the feasibility of conducting an
evaluation trial of an integrated intervention to address
both substance use and IPA perpetration to men in sub-
stance use treatment.
Design
A multicentre, parallel group, individually randomised
controlled feasibility trial with a nested formative evalu-
ation, comparing an integrated intervention to reduce
IPA + usual substance use treatment, to usual substance
use treatment only for men in substance use treatment.
Setting and participants
One hundred eight male participants will be recruited
from NHS and voluntary organisation community sub-
stance use treatment services in three regions in England
(two services in London, two services in the West Mid-
lands and two services in the South West). Sets of up to
18 men per treatment service will randomised. Three sets
of the 16-week ADVANCE intervention, one in each re-
gion, will be completed (cycle 1) and a formative evalu-
ation undertaken to inform the implementation of cycle 2
(a further three sets of the intervention, one in each re-
gion). Up to 18 men per set will randomised per cycle.
The female current or former partners of men re-
cruited to the trial will be offered support from an inte-
grated safety service and invited to provide outcome
data for the trial. Based on recruitment figures from
other evaluations of perpetrator programs [34] and a re-
cent UK-based perpetrator intervention [35], it is esti-
mated that up to 70% of their current or former female
partners will be recruited (n = 76).
Inclusion and exclusion criteria
Men attending the substance use treatment services are
eligible if:
1. They have perpetrated IPA towards a current or ex
female partner in the last 12 months
2. Have had face-to-face/phone/text/social media con-
tact at least once with that partner in the last 12
months
3. Plan to stay in the current location for the next 6
months
4. Agree to provide contact details of current and/or
ex female partner
5. Able to understand and communicate in English
Men will be excluded if any of the following apply:
1. Current restraining orders prohibiting them or
anyone on their behalf (e.g. the women’s support
worker or the researcher) from contacting their
current or ex female partner
2. Pending court cases for IPA as it is uncertain how
they will be sentenced (i.e. they may not be able to
participate in the trial)
3. Pending child protection hearings to ensure that
participating in the trial could not be used to
influence proceedings
4. Attending an intervention for IPA perpetration
For eligible men following the screening, the keywor-
ker at the substance use treatment service will assess
men’s suitability to participate in the trial.
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Table 1 SPIRIT Checklist
Section/item Item
no.
Description Addressed on
page number
Administrative information
Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial
acronym
Title page
Trial registration 2a Trial identifier and registry name. If not yet registered, name of the intended registry Abstract, 2
Protocol version 3 Date and version identifier 4
Funding 4 Sources and types of financial, material, and other support 25
Roles and responsibilities 5a Names, affiliations, and roles of protocol contributors Title page, 25–26
5b Name and contact information for the trial sponsor 24
5c Role of study sponsor and funders, if any, in study design; collection, management, analysis,
and interpretation of data; writing of the report; and the decision to submit the report for
publication, including whether they will have ultimate authority over any of these activities
25
5d Composition, roles, and responsibilities of the coordinating centre, steering committee,
endpoint adjudication committee, data management team, and other individuals or groups
overseeing the trial, if applicable (see Item 21a for data monitoring committee)
23
Introduction
Background and
rationale
6a Description of research question and justification for undertaking the trial, including a summary
of relevant studies (published and unpublished) examining benefits and harms for each
intervention
3–4
6b Explanation for choice of comparators 12
Objectives 7 Specific objectives or hypotheses 4–5
Trial design 8 Description of trial design including type of trial (e.g. parallel group, crossover, factorial, single
group), allocation ratio, and framework (e.g. superiority, equivalence, non-inferiority, exploratory)
5
Methods: participants, interventions, and outcomes
Study setting 9 Description of study settings (e.g. community clinic, academic hospital) and list of countries
where data will be collected. Reference to where a list of study sites can be obtained
5
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres
and individuals who will perform the interventions (e.g. surgeons, psychotherapists)
5–6
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when
they will be administered
9–12
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (e.g.
drug dose change in response to harms, participant request, or improving/worsening disease)
21
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring
adherence (e.g. drug tablet return, laboratory tests)
9, 11, 21
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 12
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (e.g.
systolic blood pressure), analysis metric (e.g. change from baseline, final value, time to event),
method of aggregation (e.g. median, proportion), and time point for each outcome.
Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly
recommended
13–20
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments,
and visits for participants. A schematic diagram is highly recommended (see figure)
Fig. 1, Table 2
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was
determined, including clinical and statistical assumptions supporting any sample size
calculations
21–22
Recruitment 15 Strategies for achieving adequate participant enrolment to reach the target sample size 7–9, 21
Methods: assignment of interventions (for controlled trials)
Allocation:
Sequence generation 16a Method of generating the allocation sequence (e.g. computer-generated random numbers),
and list of any factors for stratification. To reduce the predictability of a random sequence, de-
tails of any planned restriction (e.g. blocking) should be provided in a separate document that
is unavailable to those who enrol participants or assign interventions
9
Allocation 16b Mechanism of implementing the allocation sequence (e.g. central telephone; sequentially 9
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Table 1 SPIRIT Checklist (Continued)
Section/item Item
no.
Description Addressed on
page number
concealment
mechanism
numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until
interventions are assigned
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign
participants to interventions
9
Blinding (masking) 17a Who will be blinded after assignment to interventions (e.g. trial participants, care providers,
outcome assessors, data analysts), and how
9
17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a
participant’s allocated intervention during the trial
n/a
Methods: data collection, management, and analysis
Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any
related processes to promote data quality (e.g. duplicate measurements, training of assessors)
and a description of study instruments (e.g. questionnaires, laboratory tests) along with their
reliability and validity, if known. Reference to where data collection forms can be found, if not
in the protocol
7–8, 13–20
18b Plans to promote participant retention and complete follow-up, including a list of any outcome
data to be collected for participants who discontinue or deviate from intervention protocols
9, 11, 21
Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote
data quality (e.g. double data entry; range checks for data values). Reference to where details of
data management procedures can be found, if not in the protocol
20
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other
details of the statistical analysis plan can be found, if not in the protocol
22
20b Methods for any additional analyses (e.g. subgroup and adjusted analyses) 22
20c Definition of analysis population relating to protocol non-adherence (e.g. as randomised ana-
lysis), and any statistical methods to handle missing data (e.g. multiple imputations)
22
Methods: monitoring
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure;
statement of whether it is independent from the sponsor and competing interests; and
reference to where further details about its charter can be found, if not in the protocol.
Alternatively, an explanation of why a DMC is not needed
23
21b Description of any interim analyses and stopping guidelines, including who will have access to
these interim results and make the final decision to terminate the trial
21
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported
adverse events and other unintended effects of trial interventions or trial conduct
21
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be
independent from investigators and the sponsor
n/a
Ethics and dissemination
Research ethics approval 24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 25
Protocol amendments 25 Plans for communicating important protocol modifications (e.g. changes to eligibility criteria,
outcomes, analyses) to relevant parties (e.g. investigators, REC/IRBs, trial participants, trial
registries, journals, regulators)
25
Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised
surrogates, and how (see Item 32)
7-8
26b Additional consent provisions for collection and use of participant data and biological
specimens in ancillary studies, if applicable
n/a
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared,
and maintained in order to protect confidentiality before, during, and after the trial
24
Declaration of interests 28 Financial and other competing interests for principal investigators for the overall trial and each
study site
26
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual
agreements that limit such access for investigators
n/a
Ancillary and post-trial
care
30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer
harm from trial participation
n/a
Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare n/a
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For women whose current or former partners are par-
ticipating in the trial, inclusion criteria include
1) Being aged 18 years or older
2) An ability to understand and communicate in
English
Women will be excluded if any of the following apply:
1) Pending court cases for IPA
2) Pending child protection hearings
In exceptional circumstances, clinicians can override
the inclusion criteria to ensure that female current or
former partners are safeguarded including (1) where the
female and male participant share a mobile phone and
(2) where the female partner lives outside the UK and
therefore integrated safety support cannot be provided—
neither will be eligible to take part in the feasibility trial.
Male current or former partners and non-English
speaking female current or former partners of men in
the trial will not be invited to provide outcome data but
will be offered support for their IPA victimisation.
Recruitment
Participation in the trial requires a two-stage informed
consent. Firstly, men must consent to be screened for
eligibility. If eligible after screening, men then consent to
take part in the trial. Researchers will screen potential
male participants for eligibility using the Revised Abu-
sive Behavior Inventory [36]. Men already attending sub-
stance use treatment will be identified in substance use
treatment waiting rooms, via keyworkers or will contact
researchers from details on flyers/posters advertising the
research (Fig. 1). Researchers will also attend support
groups delivered in the substance use service to explain
the study and invite interested men to discuss the study
further. Men who report this is their first appointment
at the service will not be screened as they may not be
enrolled in the service following assessment. To be
eligible to participate in the trial, male participants have
to be receiving treatment from the participating sub-
stance use service.
Researchers will explain the study to interested men,
provide them with an information sheet and gain in-
formed consent to undertake the screening, including
limitations to confidentiality and consent to discuss the
screening and their suitability to take part in the trial
with their keyworker. Consent forms will be counter-
signed in triplicate by both the male participant and the
researcher. Male participants will receive a copy of the
signed consent form; a copy will be filed in the Investi-
gator Site and a copy will be attached to the letter to the
male participant’s keyworker at the substance use treat-
ment service. This letter will inform the keyworker that
their client has screened positive for past year IPA and
identify areas of risk (e.g. threat/use of a weapon against
partner or choking/strangulation of partner) for poten-
tial further assessment by the keyworker. It will also in-
clude the name of their client’s current and/or former
female partner. Keyworkers then are able to consider the
suitability of their client to participate in the trial (e.g.
cognitive deficit or mental health problems that may
limit their ability to participate).
If eligible, following screening and their keyworkers
deem the participant suitable to take part, male partici-
pants will complete a baseline assessment administered
by the researcher (see Section 3.14). The researcher will
again explain the study to eligible men, provide them
with an information sheet and get their informed con-
sent to participate in the trial prior to administering the
baseline questionnaire. In addition, men will complete a
consent quiz [37] to ensure they understand the trial
procedures. Researchers will clarify any incorrect re-
sponses with the participant. Men will be randomised to
treatment conditions following baseline assessment.
Their keyworkers will be informed of which group they
have been allocated to by a letter from the researcher.
All interviews with men will be conducted in a private
room of the substance use treatment service.
Table 1 SPIRIT Checklist (Continued)
Section/item Item
no.
Description Addressed on
page number
professionals, the public, and other relevant groups (e.g. via publication, reporting in results
databases, or other data-sharing arrangements), including any publication restrictions
31b Authorship eligibility guidelines and any intended use of professional writers n/a
31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statis-
tical code
n/a
Appendices
Informed consent
materials
32 Model consent form and other related documentation given to participants and authorised
surrogates
On request
Biological specimens 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or
molecular analysis in the current trial and for future use in ancillary studies, if applicable
n/a
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Following baseline assessment and randomisation of
male participants, their current or former female part-
ners will be contacted by telephone by an integrated
safety service worker to (1) inform them their current or
former partner is participating in the trial; (2) to offer
them support for IPA victimisation; and (3) invite them
to participate in the research by providing outcome data.
Women can accept the offer of support without partici-
pating in the research and vice-versa. If women are in-
terested in participating in the research, their contact
Fig. 1 Flow of participants through the trial
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details will be passed to the research team, who will con-
tact them within 1 week and arrange a time for an initial
interview to be conducted with the researcher (see Sec-
tion 3.14). At this meeting, the researcher will explain
the trial to the woman and gain informed consent prior
to administering the baseline interview. Women will be
interviewed in a women’s support service, a substance
use treatment service, a children’s centre, or in excep-
tional cases, it may be possible for two researchers to
interview the women in her home.
After each interview, male and female participants will
be given contacts for local and national helplines and
services. If specific risk issues are identified within the
baseline assessment, appropriate steps will be taken to
manage this risk, including disclosure to the participant’s
keyworker (for male participants), and/or to the inte-
grated safety worker (for women participants).
Follow-up
Male and female participants will be followed-up at the
end of the intervention (approximately 4 months post-
randomisation) (Table 2). Reminder telephone calls or
texts will be sent in advance to arrange and confirm a
time for follow-up interview.
Method of randomisation
Male participants will be allocated to the intervention
group+ substance use treatment as usual (TAU) or TAU
only (ratio 1:1) by site via an independent online system
based at the Clinical Trials Unit. Allocation will be at
the level of the individual participant, using randomly
varying block sizes, stratified by a combination of sites
and cycles (18 participants per site/cycle stratum).
Blinding
The statisticians will be blind to the trial condition
throughout the feasibility trial. The health economists
will not be blind to the allocation as the intervention
costs will have to be assigned to the correct treatment
arm. Researchers will not be blind to the group alloca-
tion of participants, as they will also be responsible for
participant recruitment and reminder telephone calls to
attend intervention sessions.
Intervention arm
The TIDieR (Template for Intervention Description and
Replication) Checklist was used to describe the interven-
tion [38] (Additional file 1: Table S3). The Behaviour
Change Wheel, incorporating the COM-B model
Table 2 Schedule of enrolment, interventions, and assessments
Study phase
Timepoint Screening Baseline and randomisation Intervention delivery Follow-up
Enrolment:
Informed consent X X
Eligibility screen X
Baseline interview X
Allocation X
Follow-up interview X
Interventions: (16 weeks)
Intervention + TAU
TAU
Assessments:
Childhood X
Substance use X (males only) X X
Mental health X X
Intimate partner abuse X (males only) X X
Quality of life X X
Service use X X
Desirable responding X (males only) X (males only)
Motivation to change behaviour X (males only)
Self-management X (males only) X (males only)
Therapeutic alliance X (males in intervention arm only)
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(capability, opportunity, and motivation for behavioural
interventions) was used to provide a framework to de-
velop the ADVANCE intervention [39]. The ADVANCE
intervention is voluntary, i.e. men are not mandated to
attend by the court. Within the COM-B model, the
intervention thus considered how capability, opportun-
ity, and motivation for each could be addressed and
which type of intervention would be best to enact each.
Thus, modelling, enablement, education, incentivisation,
and training are included in the intervention. In the AD-
VANCE intervention, the capability is enhanced by increas-
ing participants’ knowledge and skills based on the self-
regulation model. In particular, awareness around crisis
planning and self-management is raised and automatic
thoughts and beliefs are challenged by evaluating the conse-
quences. Opportunity is provided to model and promote
positive behaviour within intervention sessions, and out-of-
session tasks to generalise learning. Each week, sessions
were reviewed to reinforce positive achievements. Finally,
goal planning is used to motivate participants and
reinforcement of motivation is achieved through ongoing
personal support and incentives. The ADVANCE interven-
tion is manualised comprising 2–4 individual sessions (2
need to be completed before beginning the group interven-
tion) with a keyworker to set goals, develop a personal
safety plan, and increase motivation and readiness followed
by a 12-week group intervention (Fig. 2) (Gilchrist E,
Johnson A, Stephens-Lewis D, Kirkpatrick S, McMurran
M, Gilchrist G: Designing an implementation intervention
with the Behaviour Change Wheel for Men in Substance
Use Services who have been abusive to an intimate female
partner, in preparation). Given the high level of trauma,
family disruption, abuse, and neglect in this population, in-
terventions targeting IPA in men who use substances re-
quire a trauma-informed approach [40]. Recent approaches
with forensic populations indicate that strengths-based ap-
proaches, designed for a range of learning styles, avoiding
shame and judgement are more effective [41, 42]. Three
potential targets for effective IPA change were identified as
being reducing pro-abuse attitudes including locating caus-
ality for abuse in substance use, managing distress individu-
ally and pro-socially, and learning effective, non-abusive
behavioural responses within relationship negotiations. The
ADVANCE intervention focuses on developing partici-
pants’ strengths and developing healthy, non-abusing rela-
tionships. Two main models to enable change were
selected (1) personal goal setting, to work with individual
goals, and to build genuine motivation through alignment
with personal values and facilitate change by breaking lar-
ger longer-term aims into specific small steps that can be
more easily achieved, reinforcing motivation through these
small achievements and (2) informed by the self-regulation
model which suggests that building self-management in
one domain enables more effective self-management across
other domains. The intervention requires individuals to set
specific goals for reducing risk, such as changing substance
use, and for developing a prosocial lifestyle in terms of
work, leisure, health, and accommodation. Underpinning
the goal-focused approach is the need to improve self-
regulation of behaviours, achieved by identifying and chan-
ging cues, appraisals (thoughts), emotions, behaviours, and
consequences. Throughout the ADVANCE intervention,
behaviour change skills are introduced and practised. The
12 group sessions will address the following:
 Session 1. Introduction to the group
 Session 2. Managing myself
 Session 3. Behaviour analysis + gender
 Session 4. Impact of intimate partner abuse
 Session 5. Children, parenting, substance use +
intimate partner abuse
 Session 6. Relating
 Session 7. Improving communication
 Session 8. Dealing with distress
 Session 9. Planning to be better
 Session 10. Positive relationships
 Session 11. New futures, peoples plans + positive
activities
Fig. 2 ADVANCE intervention
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 Session 12. Recap what we have learned
Pre-group individual sessions will be delivered by key-
workers in substance use treatment service. The group
intervention will also be delivered in substance use treat-
ment services by two trained facilitators, where possible
one female and one male. Keyworkers or facilitators will
check-in by phone with participants between group ses-
sions to address any issues arising during the session.
Participants will be given out of session practice exer-
cises. Facilitators will send a weekly feedback to partici-
pants’ keyworkers by email after each session to update
them on progress, safeguarding issues and risk. Group
sessions will be video recorded with participants’ con-
sent and checked for fidelity. Only those consenting to
being video recorded would be able to take part in the
trial.
Fortnightly, integrity support meetings will be held
with facilitators to discuss delivery issues and address
any expected problems for delivery of the next two ses-
sions. Four case management meetings will take place
with facilitators (and keyworkers where possible) and the
integrated safety service workers over the course of the
intervention to consider risk. Aftercare is provided in
the form of workbooks for men, keyworker guidance,
and signposting.
Contingency management, recommended by the Na-
tional Institute for Health and Care Excellence [43], will
be used to encourage motivation and retention of partic-
ipants in the group intervention by offering incentives to
attend the ADVANCE integrated intervention. Partici-
pants in the intervention arm only will receive a £5 vou-
cher (for a shop or service of their choosing) for
attending each of the 12 sessions up to a total of £60.
These will be awarded at session 6 and session 12 of the
group intervention. If a participant attends all 12 ses-
sions an additional £10 ‘bonus’ voucher will be available.
Travel will also be reimbursed, and refreshments
provided.
The integrated safety service will also contact the fe-
male current or former partners of males in the inter-
vention arm on at least three occasions to update them
on their current or ex-partner’s overall progress within
the intervention. They will also contact women if there
is anything that they need to know to keep themselves
and their families safe.
Control arm
Men in both treatment arms will receive substance use
TAU including group work, individual sessions, mutual
aid, and opiate substitution treatment. Integrated safety
services and individualised support are offered to all par-
ticipants’ female current or ex-partners as needed,
regardless of the allocation to a group of their male
partners.
Data from naturalistic studies found that the relative
risk for IPA after substance use treatment was 2–3 times
greater amongst those who relapsed compared to those
who successfully completed treatment [44], potentially
as a result of a reduction in alcohol use and improved
relationship functioning. Therefore, the selection of sub-
stance use TAU as a comparator for this feasibility study
is justified. Moreover, men’s keyworker’s will be in-
formed that their client has perpetrated IPA in the past
12 months regardless of group allocation and may
choose to address this as part of TAU.
Fidelity
All group intervention sessions will be video recorded
with participants’ and facilitators’ consent. Facilitators’
fidelity of the delivery of the intervention manual will be
assessed by a trained observer using a pre-defined check-
list for each session of the intervention. Video recordings
will allow the same observer to assess treatment integ-
rity, the degree to which treatment is implemented as
intended across sites. Sessions are videotaped for assess-
ment of treatment fidelity, therapist skill, and compe-
tency in delivering the interventions and the
discriminability of the study treatments. Treatment fidel-
ity will be assessed using an adapted form of the Yale
School of Medicine Adherence and Competence Scale
[37], shown to be successful at discriminating key ther-
apy content and skill domains [38]. A series of checklists
are created to tap into key unique components of spe-
cific therapies (e.g. experimental condition vs. control)
as well as a series of scales tapping common factors (e.g.
assessment of substance use and general functioning).
Formative evaluation
At the end of each group session, men will be asked to
self-complete a brief evaluation form. Facilitators will
complete a brief treatment adherence form after each
session. All TAU contacts will be recorded by keywor-
kers for men (regardless of treatment arm). Integrated
safety support workers will record contacts with the
current or ex female partners of men in both treatment
arms. Focus groups with staff at the end of each cycle of
the intervention will examine their experiences of deliv-
ering the intervention. After completion of the first cycle
of the intervention at each site, interviews with partici-
pants will explore their experiences and acceptability of
attending the intervention and participating in the trial.
Feasibility measures
The primary objective of this study is to demonstrate
the feasibility of conducting a trial to evaluate the inter-
vention, including the feasibility and acceptability of
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delivering the intervention in substance use treatment
and the feasibility of outcome measure collection on
perpetrators and their current or former female partners.
The following feasibility parameters will be examined:
rates of consent, recruitment, and follow-up by site and
group allocation. The estimation of background variabil-
ity will inform sample size calculations for a future
evaluation trial.
Men’s TAU attendance for both treatment arms, at-
tendance, and retention in the ADVANCE intervention
for men allocated to the treatment arm, and numbers of
current or former female partners accepting the offer of
support from the integrated safety service will also be
collected.
The understandability and acceptability of potential
outcome measures for use in a future trial will be con-
sidered by exploring (1) completeness of data; (2) re-
searchers’ perception of participants’ understanding (i.e.
of language used and meaning of questions); and (3) re-
searchers’ perception of participants’ acceptability (i.e.
participant refuses to answer or gets annoyed/frustrated
or asks to end the interview) of each measure.
Outcome measures
The suitability and acceptability of outcome measures
will be assessed to determine the feasibility of including
them in a future effectiveness trial. Researchers’ percep-
tions of participants’ understanding (e.g. of language and
meaning of questions) and acceptability (e.g. if partici-
pant refuses to answer or gets annoyed/frustrated or
asks to end the interview) will be recorded for each out-
come measure using a pre-determined rating scale (1—
lowest rating to 3—highest rating for understanding and
acceptability). The following outcomes measures will be
assessed at baseline for men and initial interview for
women and at the end of the intervention (4 months
post-randomisation of men) for men in both treatment
arms and their current or former female partners (unless
otherwise specified) (Table 2).
Substance use
The Alcohol Use Disorders Identification Test (AUDIT)
(included in the baseline questionnaire only) is a 10-item
screening tool used to assess alcohol use in the past 12
months [45]. Scores range from 0 to 40. Total scores of
8 or more for men (7 or more for women) indicate haz-
ardous and harmful alcohol use, and scores of 20 or
above indicate alcohol dependence.
The Drug Use Disorders Identification Test (DUDIT)
(included in the baseline questionnaire only) is an 11-
item screening tool used to identify drug-related prob-
lems [46]. Scores range from 0 to 44. Total scores of 6
or more for men (2 or more for women) indicate drug-
related problems, and scores of 25 or more indicate drug
dependence.
As the AUDIT and DUDIT assess substance use in the
past 12 months they will not be used to measure sub-
stance use outcomes post-intervention (4 months post-
randomisation). Instead, the average amount on a using
day and number of days substances used in each of the
past 4 weeks will be recorded using the Treatment Out-
come Profile [47] at baseline and follow-up. The number
of days in the past 4 weeks that problems with particular
substances will also be recorded using The Addiction Se-
verity Index [48] as will current treatment for substance
use.
Mental health
The Patient Health Questionnaire (PHQ-9) is a 9-item
scale measuring depressive symptoms in the past 2
weeks [49]. The total score ranges from 0 to 27. A score
≥ 10 has a sensitivity of 88% and a specificity of 88% for
major depression.
The Generalised Anxiety Disorder Assessment (GAD-7)
is a 7-item scale measuring general anxiety symptoms in
the past 2 weeks [50]. The total score ranges from 0 to
21. A score of ≥ 10 represents a reasonable cut point for
identifying cases of GAD.
The Primary Care Post-Traumatic Stress Disorder
(PTSD) Screen (PC-PTSD-5) is a 5-item screen for PTSD
in the past month, with scores ranging from 0 to 5 [51].
A score of ≥ 3 indicates PTSD.
The Standardised Assessment of Personality—Abbrevi-
ated Scale (SAPAS) (included in male baseline question-
naire only) is an 8-item screening interview for
personality disorder [52] enquiring about a person’s be-
haviour in general rather than a specific time frame.
Scores range from 0 to 8. A score ≥ 3 correctly identified
the presence of DSM-IV personality disorder in 90% of
participants.
Intimate partner abuse (victimisation and perpetration) in
the past 4 months
The Abusive Behaviour Inventory Revised (ABI-R) is a
25-item reliable tool to measure experiences of physical
(13 items), psychological (9 items), and sexual abuse (3
items) victimisation and perpetration [36]. Each item
can be scored from 1 (never) to 5 (very frequently). The
higher the score on each subscale, the greater the fre-
quency of abuse.
Controlling behaviours in relation to both perpetration
and victimisation will be assessed using four adapted
questions from the 24 item Revised Controlling Behav-
iours Scale (CBS-R) [53]: smash your partner’s property
when annoyed/angry; want to know where your partner
went and who they spoke to when not together; tell your
partner they were going mad; and try to restrict time
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your partner spent with family or friends. Total score for
the 4 questions ranges from 0 to 16; the higher the
score, the greater the frequency of a partner using con-
trolling behaviours.
The Communications Patterns Questionnaire-Short
Form (CPQ-SF) [54] is an 11-item self-assessment of
“spouses’ perceptions of marital interactions … to indicate
the representativeness of that description for the conflict
and communication patterns in their relationship”: male
demand/female withdraw; female demand/male withdraw;
original total demand/withdraw; alternate demand/with-
draw; criticise/defend and positive interaction. Higher
scores on each subscale suggest which communication
pattern is likely to be used during conflict interactions.
Two scales (9 items) from The Intimate Partner Vio-
lence Responsibility Attribution Scale (IPVRAS) (included
in the male baseline and follow-up questionnaires only)
will assess perpetrators’ responsibility attribution to the
victim (V) and responsibility attribution to the offender’s
(i.e. perpetrator’s) personal context (O) [55]. The higher
the score, the more responsibility attributed to the victim
(V) or offender’s personal context (O).
The 12-item anger subscale from The Propensity for
Abusiveness Scale (PAS) (included in the male baseline
and follow-up questionnaires only) is included. The PAS
predicts the perpetration of physical and emotional
abuse. Scores on the anger subscale range from 12 (com-
pletely undescriptive of you) to 60 (completely descrip-
tive of you) [56].
Two questions from a non-validated scale on the use of
social media in relation to perpetration and victimisation
of a partner will be included [57] (e.g. ‘Used mobile tech-
nology to check her location’). Total scores range from 2
(never) to 10 (very frequently); the higher the score, the
greater the frequency of abuse using social media.
Four questions will be used from a non-validated scale
will assess the use of children against a partner [35] (e.g.
“Asked the children to report on what your current or
former partner is doing or where she has been”). Total
scores range from 4 (never) to 20 (very frequently); the
higher the score, the greater the frequency of using chil-
dren against a partner/the greater the frequency of hav-
ing a partner use children against you.
There will be a question on the frequency of stopping
a partner from leaving the house against their will/being
stopped from leaving the house will be scored from 1
(never) to 5 (very frequently). Two questions on stalking
behaviours scoring from 2 (never) to 5 (very frequently);
the higher the score, the greater the frequency of experi-
encing or perpetrating stalking behaviour.
Self-management
The 13-item Brief Self-Control Scale (BSCS) enquires
about typical dispositional self-regulatory behaviours
using two factors of self-control: restraint and impulsiv-
ity [58] (included in the male baseline and follow-up
questionnaires only). Total scores range from 13 (not at
all like me) to 65 (very much like me).
Quality of life
The ICEpop CAPability measure for Adults (ICECAP-A)
is used to assess a person’s well-being using a capability
approach [59]. It has five attributes: attachment (an abil-
ity to have love, friendship, and support); stability (an
ability to feel settled and secure); achievement (an abil-
ity to achieve and progress in life); enjoyment (an ability
to experience enjoyment and pleasure), and autonomy
(an ability to be independent), each with four levels of
capacity. Tariff values range from 1 (full capability) to 0
(no capability).
The EQ-5D-3L consists of a descriptive system and a
Visual Analogue Scale (VAS). The descriptive system as-
sesses five dimensions of a person’s health state (mobil-
ity, self-care, usual activities, pain/discomfort, and
anxiety/depression) on the day of administering, each
with three response levels: no problems, some problems,
and extreme problems [60]. The tariff index score based
on the descriptive profile ranges from 1 (perfect health)
to – 0.594 (worst health), with death anchored at 0 for
the UK valuation set [61]. The EQ VAS records the re-
spondent’s current self-rated health on a vertical visual
analogue scale from 0 (worst imaginable health) to 100
(best imaginable health).
Healthcare, social, and other legal and civil services use
and criminal justice contacts
Participants’ utilisation of primary and secondary health-
care, social services, and other legal and civil services, in-
cluding the prescribing of medication, and their contacts
with criminal justice will be recorded retrospectively by
self-report questionnaire.
Experience of the group intervention (males allocated to
the intervention arm, follow-up questionnaire only)
The 12-item Working Alliance Inventory–Short Revised
(WAI-SR) client version measures three key aspects of
therapeutic alliance: agreement on the tasks of therapy,
agreement on therapy goals, and affective bond develop-
ment [62]. Scores range from 5 to 60, with higher scores
indicating a better therapeutic alliance between client
and therapist. The patient version of the California Psy-
chotherapy Alliance Scale- Short Form [63] has 12 items
that measures the alliance in psychotherapy across 4
subscales: the patient working capacity, patient commit-
ment, working strategy consensus, and therapist under-
standing and involvement. The total score is the mean
of these four subscales.
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The following will also be assessed and may be used as
explanatory variables.
Socio-demographic information
Data on participants’ relationship status, age, gender,
ethnicity, highest education level attained, living arrange-
ments, current employment status, number of children,
and their living arrangements will be recorded.
Childhood
The occurrence of ten Adverse Childhood Experiences
(ACE) (e.g. physical, sexual, emotional abuse, neglect,
household dysfunction) experienced before the age of 18
were assessed to produce an ACE score of cumulative
childhood stress [64] (assessed in baseline questionnaire
only). Scores range from 0 to 10; the higher the score
the greater the childhood adversity experienced.
Desirable responding
The Balanced Inventory of Desirable Responding Short
Form (BIDR-SF) [65] (administered to male participants
only). The BIDR-SF consists of two subscales: Self-
Deceptive Enhancement (honest but overly positive
responding) and Impression Management (bias toward
pleasing others or ‘deliberate self-presentation’). Higher
scores indicating more desirable responses. IPA scores
will be adjusted for BIDR-SF scores.
Motivation to change behaviour
The URICA-Domestic Violence (URICA-DV) was ad-
ministered to male participants only) is a 32-item meas-
uring perpetrators’ readiness to end their violence [66].
URICA-DV includes four subscales to measure stages of
change pre-contemplation, contemplation, action, and
relapse. Responses are given on a 5-point Likert scale
ranging from 1 (strong disagreement) to 5 (strong
agreement).
Database systems
A web based electronic Case Report Forms system
(InferMed MACRO) will be used to collect baseline and
outcome data. The system is Good Clinical Practice
compliant with full audit trail and database lock func-
tionality and a range of validations will be programmed
to minimise data entry errors. No data analysis will be
undertaken until databases are locked.
Ten percent of coded questionnaires and 10% of en-
tered data by site will be verified by the trial manager to
check for errors. If coded questionnaires and data en-
tered are found to contain errors, a further 10% will be
checked.
Ethical issues
The trial will be conducted in compliance with the prin-
ciples of the Declaration of Helsinki [67], the principles
of Good Clinical Practice, and all of the applicable regu-
latory requirements (UK data protection laws (meaning
the Data Protection Act 1998 until 24 May 2018, and
from 25 May 2018 the European Union General Data
Protection Regulation (GDPR) and applicable UK legisla-
tion that enshrines GDPR into UK law).
As part of the informed consent process, participants
will be advised and provided guidance about confidenti-
ality and the limits to it. Significant risk of future harm
to self or others will be disclosed to their keyworker or
the duty worker in the substance use service or the inte-
grated safety service where the interview is taking place,
or to the relevant authorities.
The trial may be prematurely discontinued by the
Sponsor or Chief Investigator on the basis of new safety
information or for other reasons given by the Data Mon-
itoring and Ethics Committee/Trial Steering Committee,
regulatory authority or ethics committee concerned. The
trial may also be prematurely discontinued due to lack
of recruitment or upon advice from the Trial Steering
Committee. If the study is prematurely discontinued, ac-
tive participants will be informed and no further partici-
pant data will be collected.
All serious adverse events resulting from participation
in the trial will be reported to the Ethics Committee
within 48 h of receiving the report.
Research reimbursement
Male and female participants will be reimbursed in cash
or vouchers for their time for completing baseline or
follow-up interviews (£10) and taking part in focus
groups or qualitative interviews (£20). All research par-
ticipants will receive £5 travel expenses for attending a
research interview.
Sample size calculation
The sample size for a feasibility study should allow pa-
rameters required to inform the design of the definitive
randomised controlled trial to be estimated. To estimate
a standard deviation for a sample size calculation of a fu-
ture evaluation trial, a sample of at least 50 participants
is recommended [68]. Therefore, to recruit a sample size
of 60 female current or former partners (i.e. 30 whose
current or ex male partners in the intervention arm and
30 whose partners are in the control arm), and taking a
conservative retention rate of 80% of female current or
former partners at end of intervention assessment (4
months post-randomisation), we will recruit 76 female
current or former partners. It is estimated that around
70% of current or former female partners will agree to
take part in the trial, therefore approximately 108 male
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participants will need to be recruited to obtain a sample
of 76 female current or former partners.
Statistical analysis
This feasibility trial will estimate parameters needed for
planning an efficacy trial including estimating various
rates (e.g. recruitment, randomisation, follow-rates) and
estimating the within-trial arm standard deviation, the
pre-post correlation, and the Intracluster Correlation
Coefficient (ICC) for possible outcome measures to in-
form the sample size calculation of a future randomised
control trial. Outcome measures will be rated by the re-
searcher for each participant for their suitability and ac-
ceptability and the mean scores summarised for each
outcome. Outcome measures will be described by trial
arm. Intervention effect sizes (e.g. incidence rate ratios
for the count outcome and mean differences for con-
tinuous outcome measures) will be estimated for various
outcome measures, but no formal hypotheses testing will
be carried out.
Economic analysis
The costs of providing the intervention will be collected
from local data sources to estimate the incremental cost
of delivering the ADVANCE intervention over and
above substance use TAU. Questionnaires on the use of
primary and secondary health and social care services
and contacts with criminal justice services by men (and
their female current or ex-partners) in the intervention
and control groups will record quantities of resource
use. This resource use will be multiplied by unit costs to
estimate a cost profile for each participant. The returned
questionnaires will be analysed to assess the acceptability
of data collection methods, identify barriers to data col-
lection and highlight the most commonly used services
in this population. A more appropriate questionnaire for
an efficacy trial can be developed based on the feasibility
trial data. A cost profile will be estimated for each par-
ticipant, including trial-related costs and wider service
use costs and presented by treatment arm.
Qualitative analysis
Focus groups and semi-structured interviews will be
digitally recorded and transcribed verbatim. Data will be
organised and coded using NVivo. Multiple coders will
enhance the rigour of the analysis. Framework analysis
will be used for qualitative data analysis using five steps:
familiarization; identifying a thematic framework; index-
ing; charting; and mapping and interpretation [69]. Col-
lecting multiple perspectives data (e.g. from male and
female participants, keyworkers, intervention facilitators,
and women’s support staff) in a qualitative formative
evaluation will provide a better understanding of the in-
tervention’s implementation. The framework approach
allows the exploration of patterns in themes across dif-
ferent participants and groups of participants.
Data management
In accordance with the Trial Terms of Reference, the
Data Monitoring and Ethics Committee will periodically
review overall safety data to determine patterns and
trends of events, or to identify safety issues, which would
not be apparent on an individual case basis and report
their findings to the Trial Steering Committee who will
provide overall supervision of the feasibility trial.
Data handling and storage
Participants’ contact will be stored on a secure password
protected server for 3–6 months after the study has
ended. Consent forms will be stored at each site in a
locked cabinet and will not contain the participant iden-
tification number. Paper copies of questionnaires will be
stored separately from the consent forms and contain
only a participant identification number. A unique iden-
tification code will be assigned to electronic sound files
and transcripts of the focus groups, known only to ap-
propriate members of the research team. Any personal
information required will also be coded with this identi-
fication number and kept in a password protected server.
Audio files will not contain participant’s names and will
not be stored on the recording device. Audio files will be
downloaded onto a secure server. As soon as the audio
file is checked on the server, it will be deleted from the
recording device. Any quotes published will be anonym-
ous further protecting participant confidentiality. Re-
cordings will be archived in a secure location for a
minimum period of 7 years.
Discussion
IPA remains a leading contributor to disease burden
[70]. It is estimated that the annual cost of domestic
abuse in England and Wales is over £66 billion, mainly
due to the cost of physical and emotional harms experi-
enced by victims/survivors (£47 billion) [71]. There is a
need to find effective interventions to reduce IPA per-
petration, especially amongst high-risk groups such as
substance users. Current provision of community per-
petrator groups does not meet demand nor is it tailored
to the specific needs of men in substance use treatment.
This unmet need led to the development of the AD-
VANCE intervention. It is hoped that delivering tailored
IPA interventions in substance use treatment will in-
crease their ability to reach men who may not otherwise
be referred to perpetrator interventions and result in
better outcomes for male perpetrators and improved
wellbeing for their female partners.
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This feasibility trial, and nested formative evaluation,
will inform the design of a future trial to evaluate the
clinical efficacy and cost-effectiveness trial.
Trial status
The trial sponsor is South London and Maudsley NHS
Foundation Trust. The screening began on 5 July 2018,
with the first male participant randomised on 17 July
2018. Recruitment will end on 7 May 2019.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-020-00580-7.
Additional file 1: Table S3. The TIDieR (Template for Intervention
Description and Replication) Checklist. Information to include when
describing an intervention and the location of the information
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